Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort - Scorecard - MDSpire
Advertisement
Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort
Clinical Scorecard: Comparative Analysis of Clinical Outcomes from Molecular-Targeted Treatments for Rheumatoid Arthritis: Insights from Orthopaedic Surgeons and Rheumatologists in the Multicenter Retrospective ANSWER Study
At a Glance
Category
Detail
Condition
Rheumatoid Arthritis (RA)
Key Mechanisms
Use of biologic DMARDs (TNFi, aIL-6Ra, CTLA4-Ig) and Janus kinase inhibitors (JAKi) targeting immune pathways to control inflammation and disease progression
Target Population
Patients with rheumatoid arthritis treated with bDMARDs or JAKi in Japan
Care Setting
Pharmacological management by rheumatology-oriented orthopaedic surgeons and rheumatologists in university-affiliated and community hospitals
Key Highlights
Japan uniquely employs both orthopaedic surgeons and rheumatologists certified in rheumatology to manage RA pharmacotherapy.
Treatment retention is used as a key outcome measure reflecting drug safety, efficacy, and tolerability across clinical settings.
The ANSWER cohort study compares patient characteristics, treatment patterns, and outcomes between orthopaedic surgery and rheumatology clinics.
Guideline-Based Recommendations
Diagnosis
RA diagnosis based on 1987 ACR or 2010 ACR/EULAR classification criteria.
Management
Early intervention and tight disease activity control per Japanese College of Rheumatology (JCR) guidelines.
Escalation to bDMARDs or JAKi recommended for patients not achieving low disease activity on csDMARDs, mainly methotrexate.
Drug dosages prescribed according to manufacturers’ recommendations.
Monitoring & Follow-up
Regular assessment of disease activity using CDAI and DAS28 scores at baseline and follow-up intervals (1, 3, 6, 12 months).
Monitoring for adverse events including infections, dermatologic, pulmonary, cardiovascular, hematologic, and malignancies.
Risks
Treatment discontinuation reasons include ineffectiveness, toxic adverse events, non-toxic reasons (e.g., patient preference), and remission.
Patient & Prescribing Data
RA patients treated with bDMARDs or JAKi from August 2002 to May 2023 in the Kansai region, Japan.
Treatment retention compared between orthopaedic surgeon and rheumatologist groups adjusting for confounders including demographics, disease characteristics, comorbidities, and concomitant medications.
Clinical Best Practices
Utilize board-certified rheumatology specialists for pharmacological management of RA, including orthopaedic surgeons with rheumatology certification.
Apply statistical adjustment for patient background differences when comparing treatment outcomes across care settings.
Use drug retention as a composite measure of treatment safety, efficacy, and tolerability.
Incorporate comprehensive baseline and follow-up disease activity assessments to guide treatment decisions.
